{
    "clinical_study": {
        "@rank": "134445", 
        "acronym": "Epitopes-HPV01", 
        "arm_group": {
            "arm_group_label": "patients in complete response", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Complete response is a rare event in metastatic anal cancer in the case of unresectable\n      recurrence after radiochemotherapy.\n\n      In the University Hospital Center of Besan\u00e7on, 8 patients with metastatic anal cancer were\n      treated between 2005 and 2008 by 6 cycles of chemotherapy including taxane: DCF (Docetaxel,\n      Cisplatin and 5-Fluorouracil.\n\n      In more than 90% of cases, anal cancers are related to Human Papilloma Virus (HPV)\n      infection, that is the case of this patients for which HPV16 (human papillomavirus type 16)\n      genotype   was identified within the tumor samples.\n\n      The hypothesis is that an anti-HPV response immune could be generated by chemotherapy with\n      DCF and contributed to the elimination of the tumour cells and to the increase of complete\n      responses. The aim to this study is to analyze immune response against HPV in this patients\n      in complete response."
        }, 
        "brief_title": "Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Anal Canal Cancer", 
            "Human Papillomavirus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Anus Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ECOG performance status \u2264 1\n\n          -  patient with metastatic anal cancer HPV+\n\n          -  presence of a measurable target lesion according to radiological criteria (Recist\n             V1.1)\n\n          -  patient with more than 12 months of complete remission of metastatic anal cancer\n             according to radiological criteria (Recist V1.1)after treatment by DCF regimen\n             (Docetaxel, Cisplatin and 5-Fluorouracil)\n\n        Exclusion Criteria:\n\n          -  pregnancy or lactation\n\n          -  patient with any medical or psychiatric condition or disease which would make the\n             patient inappropriate for entry into this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845779", 
            "org_study_id": "Epitope-HPV01"
        }, 
        "intervention": {
            "arm_group_label": "patients in complete response", 
            "intervention_name": "DCF regimen", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 2, 2013", 
        "location": {
            "contact": {
                "email": "christophe.borg@efs.sante.fr", 
                "last_name": "Christophe BORG, Prof", 
                "phone": "+3381615615"
            }, 
            "contact_backup": {
                "email": "m1jacquin@chu-besancon.fr", 
                "last_name": "Marion JACQUIN"
            }, 
            "facility": {
                "address": {
                    "city": "Besan\u00e7on", 
                    "country": "France", 
                    "zip": "25000"
                }, 
                "name": "Medical Oncology - University Hospital of Besan\u00e7on"
            }, 
            "investigator": [
                {
                    "last_name": "Christophe BORG, Prof", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jean-Fran\u00e7ois BOSSET, Prof", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Thierry Nguyen, Doctor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal", 
        "overall_contact": {
            "email": "christophe.borg@efs.sante.fr", 
            "last_name": "Christophe BORG, Prof", 
            "phone": "+3381615615"
        }, 
        "overall_contact_backup": {
            "email": "m1jacquin@chu-besancon.fr", 
            "last_name": "Marion JACQUIN"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Committee for the Protection of Person", 
                "France: French Health Products Safety Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "presence and characterization of anti-HPV immune responses in patients in complete remission", 
            "safety_issue": "No", 
            "time_frame": "3 months after sample"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845779"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "global survival", 
                "safety_issue": "No", 
                "time_frame": "from date to initiation of chemotherapy until the date of death for any cause assessed up to 100 months"
            }, 
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "from date to initiation of chemotherapy until the date of first documented progression, assessed up to 60 months"
            }
        ], 
        "source": "Centre Hospitalier Universitaire de Besancon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de Besancon", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}